Evidence map›Paper›PMID 38246332›Full record

ArticleExperimental eye research2024

Identification of dysregulation of sphingolipids in retinoblastoma using liquid chromatography-mass spectrometry.

Omkar Surendra Khade, Sruthy Sasidharan, Ankit Jain, Bhavani Shankar Maradani, Amit Chatterjee, Divya Gopal, Ranjith Kumar Ravi Kumar, Subramaniyan Krishnakumar, Akhilesh Pandey, Narayanan Janakiraman and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental eye research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Omkar Surendra KhadeInstitute of Bioinformatics, Bangalore, Karnataka, India; Manipal Academy of Higher Education, Mangalore, Karnataka, India.
Sruthy SasidharanInstitute of Bioinformatics, Bangalore, Karnataka, India; Manipal Academy of Higher Education, Mangalore, Karnataka, India.
Ankit JainInstitute of Bioinformatics, Bangalore, Karnataka, India.
Bhavani Shankar MaradaniDepartment of Nanobiotechnology, Vision Research Foundation, Sankara Nethralaya, Chennai, India.
Amit ChatterjeeDepartment of Nanobiotechnology, Vision Research Foundation, Sankara Nethralaya, Chennai, India.
Divya GopalDepartment of Nanobiotechnology, Vision Research Foundation, Sankara Nethralaya, Chennai, India.
Ranjith Kumar Ravi KumarDepartment of Nanobiotechnology, Vision Research Foundation, Sankara Nethralaya, Chennai, India.
Subramaniyan KrishnakumarDepartment of Nanobiotechnology, Vision Research Foundation, Sankara Nethralaya, Chennai, India; Department of Histopathology, Radheshyam Stem Cell Biology, Vision Research Foundation, Sankara Nethralaya, Chennai, India.
Akhilesh PandeyInstitute of Bioinformatics, Bangalore, Karnataka, India; Manipal Academy of Higher Education, Mangalore, Karnataka, India; Department of Laboratory Medicine and Pathology, Centre for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
Narayanan JanakiramanDepartment of Nanobiotechnology, Vision Research Foundation, Sankara Nethralaya, Chennai, India.
Sailaja V ElchuriDepartment of Nanobiotechnology, Vision Research Foundation, Sankara Nethralaya, Chennai, India. Electronic address: sailaja.elchuri@gmail.com.
Seetaramanjaneyulu GundimedaInstitute of Bioinformatics, Bangalore, Karnataka, India; Manipal Academy of Higher Education, Mangalore, Karnataka, India. Electronic address: seetaram@ibioinformatics.org.
Sankara Nethralaya · INManipal Academy of Higher Education · INInstitute of Bioinformatics · INMayo Clinic · US

Funding

DBT-Wellcome Trust India Alliance IA/CRC/20/1/600002Wellcome Trust
6 · The paper itself

Abstract

Retinoblastoma (RB) is a rare ocular cancer seen in children that counts for approximately 3% of all childhood cancers. It is found that mutation in RB1, a tumour Suppressor Gene on chromosome 13 as the cause of malignancy. Retinoblastoma protein is the target for ceramide to cause apoptosis. We studied lipidomics of two RB cell lines, one aggressive cell line (NCC-RbC-51) derived from a metastatic site and one non aggressive cell line (WERI-Rb1) in comparison with a control cell line (MIO-M1). Lipid profiles of all the cell lines were studied using high resolution mass spectrometer coupled to high performance liquid chromatography. Data acquired from all the three cell lines in positive mode were analyzed to identify differentially expressed metabolites. Several phospholipids and lysophospholipids were found to be dysregulated. We observed upregulation of hexosyl ceramides, and down regulation of dihydroceramides and higher order sphingoglycolipids hinting at a hindered sphingolipid biosynthesis. The results obtained from liquid chromatography-mass spectrometry are validated by using qPCR and it was observed that genes involved in ceramide biosynthesis pathway are getting down regulated.

Indexed as

Retinal NeoplasmsRetinoblastomaCeramidesChildHumansLiquid Chromatography-Mass SpectrometrySphingolipidsCeramidesSphingolipidsDrug resistanceGlucosyl ceramideLipidomicsMass spectrometryRetinoblastomaSphingolipids

Identifiers

PMID38246332
PMCPMC7617138
OpenAlexW4391022511

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.